Track record · closed signal

Novo Nordisk A/S (NVO) — closed signal from August 10, 2025

Target reached Published before the outcome was known, scored automatically when the window closed on November 8, 2025.

Predicted vs. what happened

NVO price · publication thesis → realized outcomesplit-adjusted

$48.89 – $50.36Entry zone — fair-value band

$50.51Published — price the day we called it

$61.93Target — the price the thesis aimed for

$62.32Peak — highest point inside the window, not a realized return

$45.68Window close — end-of-window price, context only

What happened

Target reached

Hit or exceeded the predicted growth inside the window.

Peak price

$62.32

peak on September 19, 2025 — not a realized return

Peak gain

+23.4%

peak, from the publication price

Window close

$45.68

end-of-window price, context only

Days to target

—

Window

August 10, 2025 – November 8, 2025

The thesis — published August 10, 2025

Predicted growth

+24%

over the measurement window

Target price

$61.93

the price the thesis aimed for

Entry zone

$48.89 – $50.36

the fair-value band we waited for

Price at publication

$50.51

published August 10, 2025

Confidence

63%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Novo Nordisk dropped hard after a lawsuit headline and a lower 2025 sales outlook. Meanwhile, Eli Lilly's strong pill data points to lasting demand for weight-loss drugs, which supports the story. Interest stays high, and the sharp fall could set up a short rebound. If the price pushes back above a recent ceiling, a 0-3 month bounce is possible, but legal risks still need close monitoring.

Primary drivers

Lawsuit news and lower 2025 outlook knocked the stock down sharply
Rival's pill results signal strong ongoing demand for weight-loss drugs
Investor interest is elevated; sharp drop may allow a short rebound
Court outcomes are uncertain, so risk controls are important

How it played out

NVO: target was exceeded inside the window

Lyra published NVO at 50.51 on 2025-08-10, with 24% expected growth and a 61.93 target. The thesis pointed to a sharp drop after lawsuit news and a lower 2025 sales outlook, plus continued demand for weight-loss drugs, elevated investor interest, and legal risk.

Inside the window, NVO reached a 62.32 peak on 2025-09-19, above the 61.93 target. The peak gain was 23.4%. It did not hold that move. By 2025-11-08, the stock ended at 45.68. The thesis played out on the peak, but not on the close.

What happened during the window

On 2025-10-30, The Guardian reported that Novo Nordisk made a competing bid for Metsera. On 2025-11-08, AP reported that Pfizer had won the bidding process after Novo Nordisk withdrew.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All NVO signals